Stock Track | Eli Lilly Soars 5% Intraday as Strong Q2 Earnings and Analyst Upgrades Fuel Rally

Stock Track08-06

Eli Lilly shares surged 5.13% during intraday trading on Thursday, extending a rally sparked by the company's better-than-expected second-quarter financial results and a wave of bullish analyst price target increases.

The pharmaceutical giant reported Q2 revenue of approximately $23 billion, a 48% jump from the same period last year, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound. The company's gross margin reached an impressive 86%, underscoring the profitability of its obesity and diabetes franchise. Following the results, several Wall Street firms raised their price targets, with Jefferies lifting its target to $1,440, Morgan Stanley to $1,419, and Cantor Fitzgerald to $1,410, all citing confidence in Lilly's leadership in the fast-growing weight-loss drug market.

Additional positive sentiment came from news that Amazon Pharmacy will offer Eli Lilly's Zepbound KwikPen and Foundayo pill to eligible Medicare beneficiaries for $50 a month through a new federal bridge program, potentially expanding patient access to the popular treatments.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1151134972?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-06 21:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151134972","market":"us","top_or_hot":-1,"title":"Stock Track | Eli Lilly Soars 5% Intraday as Strong Q2 Earnings and Analyst Upgrades Fuel Rally","media":"Stock Track","content":"<p>Eli Lilly shares surged 5.13% during intraday trading on Thursday, extending a rally sparked by the company's better-than-expected second-quarter financial results and a wave of bullish analyst price target increases.</p>\n<p>The pharmaceutical giant reported Q2 revenue of approximately $23 billion, a 48% jump from the same period last year, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound. The company's gross margin reached an impressive 86%, underscoring the profitability of its obesity and diabetes franchise. Following the results, several Wall Street firms raised their price targets, with Jefferies lifting its target to $1,440, Morgan Stanley to $1,419, and Cantor Fitzgerald to $1,410, all citing confidence in Lilly's leadership in the fast-growing weight-loss drug market.</p>\n<p>Additional positive sentiment came from news that Amazon Pharmacy will offer Eli Lilly's Zepbound KwikPen and Foundayo pill to eligible Medicare beneficiaries for $50 a month through a new federal bridge program, potentially expanding patient access to the popular treatments.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Eli Lilly Soars 5% Intraday as Strong Q2 Earnings and Analyst Upgrades Fuel Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Eli Lilly Soars 5% Intraday as Strong Q2 Earnings and Analyst Upgrades Fuel Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-08-06 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Eli Lilly shares surged 5.13% during intraday trading on Thursday, extending a rally sparked by the company's better-than-expected second-quarter financial results and a wave of bullish analyst price target increases.</p>\n<p>The pharmaceutical giant reported Q2 revenue of approximately $23 billion, a 48% jump from the same period last year, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound. The company's gross margin reached an impressive 86%, underscoring the profitability of its obesity and diabetes franchise. Following the results, several Wall Street firms raised their price targets, with Jefferies lifting its target to $1,440, Morgan Stanley to $1,419, and Cantor Fitzgerald to $1,410, all citing confidence in Lilly's leadership in the fast-growing weight-loss drug market.</p>\n<p>Additional positive sentiment came from news that Amazon Pharmacy will offer Eli Lilly's Zepbound KwikPen and Foundayo pill to eligible Medicare beneficiaries for $50 a month through a new federal bridge program, potentially expanding patient access to the popular treatments.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LLY","symbol_name":"礼来","start_time":0,"source_url":"","article_id":"1151134972","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151134972","pubTimestamp":1786024164,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Eli Lilly shares surged 5.13% during intraday trading on Thursday, extending a rally sparked by the company's better-than-expected second-quarter financial results and a wave of bullish analyst price...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LLY":"礼来"},"translate_title":"股票跟踪 | 由于第二季度盈利强劲和分析师上调燃料反弹，礼来公司盘中飙升 5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"Eli Lilly shares surged 5.13% during intraday trading on Thursday, extending a rally sparked by the company's better-than-expected second-quarter financial results and a wave of bullish analyst price target increases.\nThe pharmaceutical giant reported Q2 revenue of approximately $23 billion, a 48% jump from the same period last year, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound. The company's gross margin reached an impressive 86%, underscoring the profitability of its obesity and diabetes franchise. Following the results, several Wall Street firms raised their price targets, with Jefferies lifting its target to $1,440, Morgan Stanley to $1,419, and Cantor Fitzgerald to $1,410, all citing confidence in Lilly's leadership in the fast-growing weight-loss drug market.\nAdditional positive sentiment came from news that Amazon Pharmacy will offer Eli Lilly's Zepbound KwikPen and Foundayo pill to eligible Medicare beneficiaries for $50 a month through a new federal bridge program, potentially expanding patient access to the popular treatments.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151134972","isCrawlerRequest":true}